ALK and non-small cell lung carcinoma: Then, an international phase III study (PROFILE 1007) conducted in previously treated ALK-positive NSCLC patients to compare crizotinib with conventional standard treatments using docetaxel or pemetrexed showed a significantly prolonged PFS [29].